Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Llinares

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Advances in Experimental Medicine and Biology|September 9, 2010
A regulatory overview about rare diseasesJordi Llinares
Expert Review of Pharmacoeconomics & Outcomes Research|November 29, 2012
Promoting the development of drugs against rare diseases: what more should be done?Kerstin Westermark, Jordi Llinares
BMJ (Clinical Research Ed.)|January 13, 2011
Orphan drugs. EU regulationsSegundo Mariz, Jordi Llinares, Kerstin Westermark
Drug News & Perspectives|February 16, 2010
European Medicines Agency support mechanisms fostering orphan drug developmentFlorence Butlen-Ducuing, Frida Rivière, Stiina Aarum, et al.
Nature Reviews. Drug Discovery|July 30, 2021
Therapeutic genome editing: regulatory horizonsPhilip A Hines, Eleonora Agricola, Jordi Llinares Garcia, et al.
Frontiers in Medicine|May 13, 2022
Biomarkers in Medicines Development-From Discovery to Regulatory Qualification and BeyondNatalie M Hendrikse, Jordi Llinares Garcia, Thorsten Vetter, et al.
Nature Reviews. Drug Discovery|June 2, 2016
Regulatory watch: The orphan drug pipeline in EuropeThomas Morel, André Lhoir, Eline Picavet, et al.
Nature Reviews. Drug Discovery|March 16, 2013
Animal models for metabolic, neuromuscular and ophthalmological rare diseasesGuillaume Vaquer, Frida Rivière, Maria Mavris, et al.
Clinical Pharmacology and Therapeutics|July 16, 2019
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and WhyMwango Kashoki, Zahra Hanaizi, Stella Yordanova, et al.
Orphanet Journal of Rare Diseases|October 8, 2015
Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Advances in Experimental Medicine and Biology|September 9, 2010
A regulatory overview about rare diseasesJordi Llinares
Expert Review of Pharmacoeconomics & Outcomes Research|November 29, 2012
Promoting the development of drugs against rare diseases: what more should be done?Kerstin Westermark, Jordi Llinares
BMJ (Clinical Research Ed.)|January 13, 2011
Orphan drugs. EU regulationsSegundo Mariz, Jordi Llinares, Kerstin Westermark
Drug News & Perspectives|February 16, 2010
European Medicines Agency support mechanisms fostering orphan drug developmentFlorence Butlen-Ducuing, Frida Rivière, Stiina Aarum, et al.
Nature Reviews. Drug Discovery|July 30, 2021
Therapeutic genome editing: regulatory horizonsPhilip A Hines, Eleonora Agricola, Jordi Llinares Garcia, et al.
Frontiers in Medicine|May 13, 2022
Biomarkers in Medicines Development-From Discovery to Regulatory Qualification and BeyondNatalie M Hendrikse, Jordi Llinares Garcia, Thorsten Vetter, et al.
Nature Reviews. Drug Discovery|June 2, 2016
Regulatory watch: The orphan drug pipeline in EuropeThomas Morel, André Lhoir, Eline Picavet, et al.
Nature Reviews. Drug Discovery|March 16, 2013
Animal models for metabolic, neuromuscular and ophthalmological rare diseasesGuillaume Vaquer, Frida Rivière, Maria Mavris, et al.
Clinical Pharmacology and Therapeutics|July 16, 2019
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and WhyMwango Kashoki, Zahra Hanaizi, Stella Yordanova, et al.
Orphanet Journal of Rare Diseases|October 8, 2015
Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Pageof 3